This has led to the development of the J3Z-MC-OJAA study, a Phase 1/2a, multicenter, open-label, ascending-dose, first in-human study that will evaluate the safety of intratecal LY3884961 administration in patients with moderate to severe PD with at least one pathogenic GBA mutation (NCT04127578). Here, GBA1 is linked to Parkinson disease.